EurogentecManufacturer & Origin
Eurogentec is a Belgian life-science manufacturer and contract development and manufacturing organisation (CDMO), founded in 1985 and headquartered in Seraing, Belgium, in the Liège region. The company is part of the Kaneka Corporation group of Japan, combining a European research and production base with the industrial backing of a global speciality-chemicals parent.
Product Range
The Eurogentec catalogue spans the research bench through to GMP-grade material for clinical and commercial supply:
- Custom oligonucleotides — research, diagnostic and therapeutic (GMP) grades, with an extensive range of modifications and fluorescent labels
- PCR and qPCR reagents — master mixes, probes, enzymes and complete kits
- Gene synthesis and nucleic acid products — synthesis, extraction and analysis
- Custom antibody development — polyclonal, monoclonal and VHH single-domain antibodies
- Custom peptide synthesis — including modified and labelled peptides
- Recombinant proteins and protein-labelling reagents
- Assay kits for multiple research areas
- GMP biopharmaceutical manufacturing — plasmid DNA, mRNA, proteins and antibody fragments
Brand Story
Eurogentec built its early reputation on synthetic DNA. Oligonucleotide synthesis remains one of its core competencies, and the discipline required to deliver consistent, high-purity synthetic nucleic acids shaped how the business grew — first into the PCR and qPCR reagents that depend on those oligos, then outward into peptides, antibodies and recombinant proteins.
Integration into the Kaneka group marked a change in ambition. Rather than remaining solely a research-reagent supplier, Eurogentec developed regulated manufacturing capability: a customer can move a molecule from research grade, through diagnostic grade, to full GMP clinical and commercial supply without changing manufacturer — continuity that carries real weight in regulated development, where a change of supplier can mean repeating validation work.
That trajectory continued with the completion of a commercial mRNA GMP facility expansion in 2025, giving the company capacity to produce mRNA batches of up to 50 grams for clinical and commercial programmes. For laboratories in Malaysia, the practical significance is breadth: one manufacturer able to support a project from a handful of custom primers at discovery stage to regulated production material.